Compare JOF & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JOF | ACRS |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.1M | 311.0M |
| IPO Year | N/A | 2015 |
| Metric | JOF | ACRS |
|---|---|---|
| Price | $11.01 | $4.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 101.7K | ★ 2.5M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 3.33% | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.43 | $1.05 |
| 52 Week High | $12.76 | $4.89 |
| Indicator | JOF | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 66.47 |
| Support Level | $10.16 | $2.67 |
| Resistance Level | $11.00 | $4.89 |
| Average True Range (ATR) | 0.18 | 0.26 |
| MACD | 0.06 | 0.06 |
| Stochastic Oscillator | 74.68 | 98.53 |
Japan Smaller Capitalization Fund Inc is a closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investments in smaller capitalization Japanese equity securities. Its portfolio of investments consists of different sectors such as banks, chemicals, construction, electric appliances, financing business, food, Information and Communication, Utilities, Real Estate, and others.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.